ENZN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENZN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.
The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.
As of today (2024-12-15), Enzon Pharmaceuticals's 50-Day SMA is $0.09. It's 20-Day SMA is $0.08 and 200-Day SMA is $0.12.
For the Biotechnology subindustry, Enzon Pharmaceuticals's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's 50-Day SMA distribution charts can be found below:
* The bar in red indicates where Enzon Pharmaceuticals's 50-Day SMA falls into.
The formula for calculating SMA is:
SMA | = | ( P1 + P2 + ... + Pn ) | / | n |
where: Pn is the price of the stock at period n. n is the total number of periods.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzon Pharmaceuticals (OTCPK:ENZN) 50-Day SMA Explanation
Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.
SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.
Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.
Thank you for viewing the detailed overview of Enzon Pharmaceuticals's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.
Randolph C Read | director | C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022 |
Jaffrey Adam Firestone | director | C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479 |
Family Fund Couchman | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jordan Bleznick | director | C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016 |
Pearce Michael Cooper | other: See explanation of responses | 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517 |
Harper Asset Management Llc | other: See explanation of responses | 2945 S CENTER GREEN CT, G215, BOULDER CO 80301 |
Brian James Harper | other: See explanation of responses | 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301 |
Myrexis, Inc. | other: See Footnote 1 | 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020 |
Xstelos Corp. | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jonathan Couchman | 10 percent owner, other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Carl C Icahn | 10 percent owner | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160 |
Richard L Feinstein | officer: VP-Finance and PFO | |
Jonathan Christodoro | director | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
From GuruFocus
By Sydnee Gatewood Sydnee Gatewood • 12-02-2016
By Marketwired Marketwired • 09-03-2020
By gurufocus 10qk • 03-16-2011
By Marketwired Marketwired • 08-15-2020
By GuruFocus Research GuruFocus Editor • 06-22-2010
By gurufocus 10qk • 11-04-2009
By gurufocus • 02-13-2010
By gurufocus Todd Sullivan • 03-14-2008
By Marketwired Marketwired • 10-22-2020
By gurufocus 10qk • 11-04-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.